DPP4 and type 2 diabetes mellitus: Accordingly, a number of studies have been performed (or are still ongoing) to evaluate whether therapeutic approaches with other glucose-lowering drugs, including peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists, and sodium-glucose transport protein 2 (SGLT2) inhibitors, may reduce or reverse these pathophysiologic factors in T2DM patients.